ProCE Banner Activity

Phase Ib Trial: Frontline Venetoclax + Decitabine or Azacitidine in Older Patients With Untreated AML Who Are Ineligible for Intensive Chemotherapy

Slideset Download
Conference Coverage
Venetoclax with HMA active and tolerable in hard-to-treat elderly AML patients.

Released: December 05, 2018

Expiration: December 04, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology